BNP controls early load-dependent regulation of SERCA through calcineurin.
Heart failure is characterised by reduced expression of sarcoplasmic reticulum calcium-ATPase (SERCA) and increased expression of B-type natriuretic peptide (BNP). The present study was performed to investigate causality of this inverse relationship under in vivo conditions in the transversal aortic constriction mouse model (TAC). Left ventricular SERCA-mRNA expression was significantly upregulated in TAC by 32% after 6 h, but not different from sham after 24 h. Serum proANP and BNP levels were increased in TAC after 24 h (BNP +274%, p < 0.01; proANP +60%, p < 0.05), but only proANP levels were increased after 6 h (+182%, p < 0.01). cGMP levels were only increased 24 h after TAC (+307%, p < 0.01), but not 6 h after TAC. BNP infusion inhibited the increase in SERCA expression 6 h after TAC. In BNP-receptor-knockout animals (GC-A), the expression of SERCA was still significantly increased 24 h after TAC at the mRNA level by 35% (p < 0.05), as well as at the protein level by 25% (p < 0.05). MCIP expression as an indicator of calcineurin activity was regulated in parallel to SERCA after 6 and 24 h. MCIP-mRNA was increased by 333% 6 h after TAC, but not significantly different from sham after 24 h. In the GC-A-KO mice, MCIP-mRNA was significantly increased in TAC compared to WT after 24 h. In mice with BNP infusion, MCIP was significantly lower 6 h after TAC compared to control animals. In conclusion, mechanical load leads to an upregulation of SERCA expression. This is followed by upregulation of natriuretic peptides with subsequent suppression of SERCA upregulation. Elevated natriuretic peptides may suppress SERCA expression by inhibition of calcineurin activity via activation of GC-A.
Toischer
Karl
K
Abteilung Kardiologie und Pneumologie, Georg-August-Universität, Robert-Koch-Str. 40, 37075, Göttingen, Germany.
Teucher
Nils
N
Unsöld
Bernhard
B
Kuhn
Michaela
M
Kögler
Harald
H
Hasenfuss
Gerd
G
D000818:Animals; D009320:Atrial Natriuretic Factor / Q000378:metabolism; D019703:Calcineurin / Q000378:metabolism*; D006152:Cyclic GMP / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D006162:Guanylate Cyclase / Q000378:metabolism; D006333:Heart Failure / Q000201:enzymology* / Q000503:physiopathology; D060588:LIM Domain Proteins; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D009124:Muscle Proteins / Q000172:deficiency / Q000235:genetics; D009200:Myocardial Contraction; D050778:NFATC Transcription Factors / Q000235:genetics; D020097:Natriuretic Peptide, Brain / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D017461:Receptors, Atrial Natriuretic Factor / Q000172:deficiency / Q000235:genetics; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases / Q000235:genetics / Q000378:metabolism*; D013997:Time Factors; D015854:Up-Regulation
D060588:LIM Domain Proteins; D009124:Muscle Proteins; D050778:NFATC Transcription Factors; D012333:RNA, Messenger; C090114:cysteine and glycine-rich protein 3; D020097:Natriuretic Peptide, Brain; D009320:Atrial Natriuretic Factor; D019703:Calcineurin; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases; D006162:Guanylate Cyclase; D017461:Receptors, Atrial Natriuretic Factor; C091715:atrial natriuretic factor receptor A; D006152:Cyclic GMP